Keytruda, Tecentriq Get New Bladder Cancer Restrictions From FDA
The FDA announced new bladder cancer restrictions on the use of Keytruda and Tecentriq, following indications that they could lower survival rates for some patients.
The FDA announced new bladder cancer restrictions on the use of Keytruda and Tecentriq, following indications that they could lower survival rates for some patients.
Researchers indicate that they have found a causal link between nonhealing femur fractures and Fosamax side effects, providing further support for lawsuits filed by hundreds of former users of the…